The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The renowned global provider of sample and assay technologies has a market capitalization of $10.30 billion. QGEN’s earnings surpassed estimates in three of the trailing four quarters and missed on ...

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

Eli Lilly is still celebrating the FDA approval ... including Eisai's antibody-based E-2814 and small-molecule drugs from Annovis Bio (buntanetap), BioVie (bezisterim), and TauRx (HMTM).